08:41 IST
NSE
Regulatory Approval
Glenmark Pharmaceuticals Regulatory Approval
Glenmark received U.S. FDA approval to expand the use of its RYALTRIS nasal spray to pediatric patients aged 6 to less than 12 years.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd news stories on ALFA NewsRead the news →- Share price
- ₹2,293.50
- Market cap
- ₹64,728 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.0×Sector 47.4×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Product Launch 3Earnings Call 3Other Announcement 2Business Update 2Annual General Meeting 2Results Update 1Regulatory Approval 1Legal & Regulatory 1Financial Results 1Employee Stock Options 1Credit Rating 1Board Meeting Date 1
Time
1 announcement with these filters